DUSP9 Antibody #59277
- WB
- IP
Supporting Data
| REACTIVITY | H |
| SENSITIVITY | Endogenous |
| MW (kDa) | 44, 46 |
| SOURCE | Rabbit |
Application Key:
- WB-Western Blotting
- IP-Immunoprecipitation
Species Cross-Reactivity Key:
- H-Human
Product Information
Product Usage Information
| Application | Dilution |
|---|---|
| Western Blotting | 1:1000 |
| Immunoprecipitation | 1:100 |
Storage
Protocol
Specificity / Sensitivity
Species Reactivity:
Source / Purification
Background
DUSP9 has been implicated in cancer, although expression level and effect on downstream signaling pathways are varied. In colorectal carcinoma, for example, it has been shown that the levels of DUSP9 are reduced in cancerous tissue compared to normal adjacent tissue (7), and in clear cell renal carcinoma cell line and xenograft experiments decreased DUSP9 was also observed, suggesting that it may be a tumor suppressor in some cell types (8). In contrast, in some difficult to treat triple negative breast cancers, experiments suggest DUSP9 activity and expression is abnormally elevated, particularly in cancer-like stem cells in these tumors (9).
DUSP9 has also been shown to be a key suppressor of high-fat diet-induced hepatic steatosis and inflammatory responses in liver. Since no drugs have yet to be approved for NAFLD and NASH, therapeutics to increase expression of DUSP9 in liver are of interest (10).
- Camps, M. et al. (2000) FASEB J 14, 6-16.
- Theodosiou, A. and Ashworth, A. (2002) Genome Biol 3, REVIEWS3009.
- Salojin, K. and Oravecz, T. (2007) J Leukoc Biol 81, 860-9.
- Tanoue, T. et al. (2002) J Biol Chem 277, 22942-9.
- Dickinson, R.J. and Keyse, S.M. (2006) J Cell Sci 119, 4607-15.
- Wu, G.S. (2007) Cancer Metastasis Rev 26, 579-85.
- Qiu, Z. et al. (2020) Front Oncol 10, 547011.
- Luo, J. et al. (2020) Onco Targets Ther 13, 1321-1330.
- Lu, H. et al. (2018) Cancer Res 78, 4191-4202.
- Ye, P. et al. (2019) Hepatology 69, 76-93.
Limited Uses
Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.
Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.